Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Advertisement
Advertisement
Trending on Targeted Onc
1
Dr Sorbye on Separating NET G3 From NEC Before Choosing Therapy
2
Dr Lewis on Cabozantinib and Time Toxicity in Neuroendocrine Tumors
3
Oncolytic Virus SVV-001 Plus Ipi/Nivo Is Safe in High-Grade Neuroendocrine Cancers
4
FDA Sets April 2027 Decision Date for Rivoceranib Combo in HCC
5